Wednesday, 4 November 2026

Aggregated from Times of India, NDTV, Hindustan Times, India Today and more · Every source linked and credited · Updated every 15 minutes

‘U-turn out of fear’: Cong links Centre’s Agniveer move to upcoming assembly polls HT Evening Brief Nov 4: Cabinet clears 2-year Agniveer extension, Iran exempts Indian ships from Hormuz curbs, Democrats flip US Congress ‘Mann smelled of alcohol in Parliament by 11 am’: Rahul Gandhi launches all-out attack on AAP at Sangrur rally Mohit Malhotra resigns as Dabur CEO after over 30 years at the company, takes up overseas role Trump loses US Congress; Netanyahu faces deadlock at home: What happens to Iran war now?Andhra Pradesh high court seeks report on police firing at chainsaw attack accused Hemanth Cabinet Clears Extension Of 850 Fast-Track Courts For Child Abuse Cases US Midterms: Top Democrat Tells Trump Administration To “Lawyer Up” After Midterm Loss Cabinet Approves Rs 4,371-Crore Scheme To Revamp Statistical System ‘He was annoying’: Jacob Duffy’s hilarious take on Virat Kohli after India’s win

‘U-turn out of fear’: Cong links Centre’s Agniveer move to upcoming assembly pollsHT Evening Brief Nov 4: Cabinet clears 2-year Agniveer extension, Iran exempts Indian ships from Hormuz curbs, Democrats flip US Congress‘Mann smelled of alcohol in Parliament by 11 am’: Rahul Gandhi launches all-out attack on AAP at Sangrur rallyMohit Malhotra resigns as Dabur CEO after over 30 years at the company, takes up overseas roleTrump loses US Congress; Netanyahu faces deadlock at home: What happens to Iran war now?Andhra Pradesh high court seeks report on police firing at chainsaw attack accused HemanthCabinet Clears Extension Of 850 Fast-Track Courts For Child Abuse CasesUS Midterms: Top Democrat Tells Trump Administration To “Lawyer Up” After Midterm LossCabinet Approves Rs 4,371-Crore Scheme To Revamp Statistical System‘He was annoying’: Jacob Duffy’s hilarious take on Virat Kohli after India’s win

Markets

Summit stock surges on $2 billion AstraZeneca investment

viaeconomictimes.indiatimes.com29 Sept

AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upc

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.

Read the full story on economictimes.indiatimes.com ↗